Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Alnylam Pharmaceuticals announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) for zilebesiran, an investigational RNAi therapeuti...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
1 Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
Copyright © 2025. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial